Zacks Research Has Bullish Forecast for Neogen Q3 Earnings

Neogen Co. (NASDAQ:NEOG) – Stock analysts at Zacks Research raised their Q3 2025 earnings per share estimates for Neogen in a research report issued to clients and investors on Monday, March 3rd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.12 for the quarter, up from their previous estimate of $0.11. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s FY2025 earnings at $0.39 EPS.

NEOG has been the subject of several other research reports. Guggenheim initiated coverage on Neogen in a report on Thursday, December 19th. They set a “buy” rating and a $15.00 price target for the company. Piper Sandler reaffirmed a “neutral” rating and issued a $13.00 price objective (down from $16.50) on shares of Neogen in a research note on Tuesday, January 21st.

Neogen Stock Performance

NASDAQ NEOG opened at $9.54 on Thursday. The stock has a market capitalization of $2.07 billion, a PE ratio of -4.36 and a beta of 1.27. The business has a 50 day simple moving average of $11.24 and a two-hundred day simple moving average of $13.62. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.77 and a quick ratio of 2.46. Neogen has a 1-year low of $9.01 and a 1-year high of $18.58.

Neogen (NASDAQ:NEOG) last released its earnings results on Friday, January 10th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.12. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The firm had revenue of $231.30 million during the quarter, compared to analysts’ expectations of $227.16 million. During the same quarter last year, the business posted $0.11 earnings per share. The firm’s revenue was up .7% on a year-over-year basis.

Institutional Investors Weigh In On Neogen

A number of institutional investors and hedge funds have recently modified their holdings of NEOG. Harbour Investments Inc. bought a new stake in shares of Neogen during the 4th quarter worth approximately $27,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Neogen by 142.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock worth $33,000 after acquiring an additional 1,165 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Neogen by 196.7% during the 4th quarter. Blue Trust Inc. now owns 3,368 shares of the company’s stock worth $41,000 after acquiring an additional 2,233 shares during the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Neogen during the 4th quarter worth approximately $43,000. Finally, Covestor Ltd lifted its stake in shares of Neogen by 41.4% during the 4th quarter. Covestor Ltd now owns 4,103 shares of the company’s stock worth $50,000 after acquiring an additional 1,202 shares during the last quarter. 96.73% of the stock is owned by institutional investors.

Insider Activity

In other Neogen news, CFO David H. Naemura purchased 14,800 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was purchased at an average cost of $11.11 per share, with a total value of $164,428.00. Following the purchase, the chief financial officer now owns 61,434 shares of the company’s stock, valued at approximately $682,531.74. The trade was a 31.74 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John Edward Adent purchased 23,035 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were acquired at an average cost of $11.03 per share, with a total value of $254,076.05. Following the completion of the purchase, the chief executive officer now directly owns 269,164 shares in the company, valued at $2,968,878.92. The trade was a 9.36 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.13% of the company’s stock.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.